Searchable abstracts of presentations at key conferences in endocrinology

ea0022p693 | Obesity | ECE2010

The obese phenotype is associated with more severe autoimmune thyroiditis evolving towards primary hypothyroidism

Ciampolillo Anna , De Pergola Giovanni , Tarantino Lucia , Trerotoli Paolo , Giorgino Francesco

Autoimmune thyroiditis is a common disease with different clinical aspects. It has not been established whether a rapid cellular destruction, with evolution towards hypothyroidism, may be associated with specific clinical phenotypes. To clarify this point, we studied 386 consecutive patients affected by autoimmune thyroiditis diagnosed within the previous 3 years: 193 patients (170 female and 23 males, age range 57.5±12.8, Group 1) were treated with L-thyro...

ea0081p355 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

GLP-1 receptor agonists and erectile dysfunction in diabetic men with and without hypogonadism: a 1- year retrospective observational study

Lisco Giuseppe , Isabella Ramunni Maria , De Pergola Giovanni , Jirillo Emilio , Guastamacchia Edoardo , Triggiani Vincenzo , Angelo Giagulli Vito

Background: Erectile dysfunction affects nearly half of men with type 2 diabetes (T2DM), and one-third of diabetic men have hypogonadism1. As an add-on to TRT in hypogonadal men with T2DM, Liraglutide may improve erectile function2, and dulaglutide decreased the incidence of moderate and severe ED in T2DM3.Study aims: To assess the GLP-1RA effect in T2DM men complaining of ED treated with both liraglutide and dulaglutide ...

ea0090p61 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

The dual GIP/GLP-1 receptor co-agonist Tirzepatide vs GLP-1 receptor agonists as add-on to basal insulin in uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis

Lisco Giuseppe , De Tullio Anna , Disoteo Olga , De Geronimo Vincenzo , Piazzolla Giuseppina , De Pergola Giovanni , Angelo Giagulli Vito , Jirillo Emilio , Guastamacchia Edoardo , Sabba Carlo , Triggiani Vincenzo

Tirzepatide, a once-weekly dual co-agonist of Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide 1 (GLP-1) receptors, has been demonstrated to improve glucose control and reduced body weight in different therapeutic approaches. With this rapid review and meta-analysis, we systematically reviewed the efficacy and safety of injectable incretin-based therapy added to basal insulin compared to basal insulin plus background treatments titrated rigorously t...